Is lipoprotein(a) a predictor for survival in patients with established coronary artery disease? Results from a prospective patient cohort study in northern Sweden

Journal of Internal Medicine

Volumn 252, Issue 1, 2002, Pages 27-35

  Ahlbeckglader, C ^a,b   Slungabirgander, L ^a   Stenlund, H ^a   Dahlen G H ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Coronary artery disease; Lipoprotein(a); Prospective patient cohort studies; Survival analyses

Indexed keywords

ANTILIPEMIC AGENT; ANTITHROMBIN III; FIBRINOGEN; LIPID; LIPOPROTEIN A;

ADULT; AGED; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DEATH CERTIFICATE; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE FUNCTION; HUMAN; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SEDIMENTATION RATE; SURVIVAL; SWEDEN;

CORONARY ANGIOGRAPHY; CORONARY DISEASE; DEATH CERTIFICATES; FEMALE; HUMANS; LIPOPROTEIN(A); MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REGRESSION ANALYSIS; SURVIVAL ANALYSIS; SWEDEN;

EID: 0036302220     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.2002.00997.x     Document Type: Article

References (53)

1. Lipoprotein Lp(a) and the risk for myocardial infarction
2. Studies on an extra pre-beta lipoprotein fraction
3. Lipoprotein(a) as a risk factor for atherosclerotic diseases
4. Lp(a) lipoprotein as a risk factor for myocardial infarction
5. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography
6. Lipoprotein(a) and coronary heart disease: A prospective case-control study in a general population sample of middle aged men
7. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen
8. Antifibrinolytic effect of recombinant apolipoprotein(a) in vitro is primarily due to attenuation of tPA-mediated Glu-plasminogen activation
9. Antifibrinolytic activity of apolipoprotein(a) in vivo: Human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis
10. Proliferation of human smooth muscle cells promoted by lipoprotein(a)
11. Interaction of lipoprotein(a) with murine peritoneal macrophages and cultured human fibroblasts
12. Serum lipoprotein(a) concentrations are related to coronary disease progression without new myocardial infarction
13. Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein(a)
14. High serum concentration of lipoprotein(a) is a risk factor for restenosis after percutaneous transluminal coronary angioplasty in Japanese patients with single-vessel disease
15. Risk factors for restenosis after percutaneous transluminal coronary angioplasty: Role of lipoprotein(a)
16. Lipoprotein(a) in restenosis after percutaneous transluminal coronary angioplasty and coronary artery disease
17. Apolipoprotein epsilon 4 homozygosity-a determinant of restenosis after coronary angioplasty
18. Lipoprotein(a) level does not predict restenosis after percutaneous transluminal coronary angioplasty
19. Influence of serum lipoprotein(a) and homocysteine levels on graft patency after coronary artery bypass grafting
20. Atherosclerosis in angiographically 'normal' coronary artery reference segments: An intravascular ultrasound study with clinical correlations
21. Vulnerable plaque. Relation of characteristics to degree of stenosis in human coronary arteries
22. Coronary plaque disruption
23. Lipoprotein(a) as a risk predictor for cardiac mortality in patients with acute coronary syndromes
24. Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study
25. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause
26. Serum Lp(a) lipoprotein concentration is not associated with clinical and angiographic outcome five years after coronary artery bypass graft surgery
27. Serum lipids, lipoprotein(a) and apo(a) isoforms in patients with established coronary artery disease and their relation to disease and prognosis after coronary by-pass surgery
28. Coronary arteriography; method of presentation of the arteriogram report and scoring system
29. A reporting system on patients evaluated for coronary artery disease
30. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
31. Elevated serum lipoprotein(a) is a risk factor for clinical recurrence after coronary balloon angioplasty
32. Luminal loss and restenosis after coronary angioplasty. The role of lipoproteins and lipids
33. Risk factors among patients undergoing repeat aorta-coronary bypass procedures
34. Prognostic importance cholesterol levels after myocardial infarction
35. Therapy for lowering lipoprotein(a) levels
36. Pronounced lowering of serum lipid levels of lipoprotein(a) in hyperlipidemic subjects treated with nicotinic acid
37. Lipoprotein(a) and cholesterol levels act synergistically and apolipoprotein-A1 is protective for the incidence of primary acute myocardial infarction in middle-aged males
38. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia
39. Insulin response to an oral glucose load in relation to Lp(a)/pre-beta-1-lipoprotein levels in non-diabetic patients with peripheral vascular disease and in controls
40. Lipoprotein [Lp(a)] and peripheral vascular disease
41. Lipoprotein(a) and development of intermittent claudication and major cardiovascular events in men and women: The Edinburgh Artery Study
42. Apolipoprotein(a) concentrations and susceptibility to coronary artery disease in patients with peripheral vascular disease
43. Lipoprotein(a) in android obesity and NIDDM
44. Lipoprotein(a) in android obesity and NIDDM: An new member in 'the metabolic syndrome'
45. Peripheral atherosclerosis and serum lipoprotein(a) in diabetes
46. Lipoprotein(a): The really bad cholesterol?
47. Fibrinogen as a risk factor for coronary heart disease and mortality in middle-aged men and women. The Scottish Heart Health Study
48. Plasma fibrinogen level and long-term prognosis in Norwegian middle-aged patients with previous myocardial infarction. A 10 year follow-up study
49. Blodets funktionella system: Fibrinogen
50. Lp(a): An acute-phase reactant?
51. Transient changes of serum lipoprotein(a) as an acute phase protein
52. Blodets funktionella system: Antitrombin III
53. The association of anticoagulant protein concentration with acute myocardial infarction in thrombolysis in myocardial infarction phase II (TIMI II) trial